Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Virus Res. 2009 Jan 29;142(1-2):92–99. doi: 10.1016/j.virusres.2009.01.014

Table 1.

Inhibition of Nipah virus by nine novel antiviral compounds and ribavirin in 10 different cell lines.

AAHL # A549 BAEC BHK21 BSR ECV304 HeLa Hep 2 M17 MMEC Vero
7 991 13503 2574 15631 22890 6612 2384 374 3305 2783
13 2792 1452 4068 3220 7300 14053 31556 9457 4647 1153
15 3384 195650 3105 16317 874 8223 >1mM DNC >1mM 314
16 2271 7331 9472 28556 1682 7194 212242 >1mM 3388 689
18 4180 3049 >1mM >1mM 37753 1222 >1mM >1mM 8644 1856
22 4697 4903 18809 34756 32794 5348 63078 6524 4172 558
23 2900 1832 111 203.8 1275 1136 2194 377 374 1832
33 475 782 1373 2510 1923 486 5480 4188 1983 501
42 342 2235 6568 16329 1653 14827 112531 DNC 11055 3093
Rib 1292 666 1767 1031 587 1036 941 1862 1103 2524

Values are expressed as the concentration (nM) of compound exhibiting 50% inhibition (IC50) of NiV infection in vitro, determined by non-linear regression analysis after quantitative immunodetection of viral N protein expressed in ten different cell lines 24 hours post infection for six ½ log dilutions (20uM-63nM) of each compound (BHK-21 and BSR n=8, Vero n=5, all other cells n=3). Rib = ribavirin, DNC = non-linear regression curve did not converge, >1mM = IC50 value was greater than 1 mM.